ULTRASOUND THERANOSTIC AGENTS

$128,885P20FY2011RRNIH

New Mexico State University Las Cruces, Las Cruces NM

Investigators

Linked publications, trials & patents

Paper 35945496 Paper 33413202 Paper 32970688 Paper 32698776 Paper 32477832 Paper 30948020 Paper 30459950 Paper 29988966 Paper 29537985 Paper 29202010 Paper 28596988 Paper 28435884 Paper 28017970 Paper 27980706 Paper 27917001 Paper 27867225 Paper 27616940 Paper 27500505 Paper 27482613 Paper 27429860 Paper 27065631 Paper 27022155 Paper 26791949 Paper 26756039 Paper 26373051 Paper 26206334 Paper 26071482 Paper 25993322 Paper 25954817 Paper 25750934 Paper 25750914 Paper 25722857 Paper 25688296 Paper 25631077 Paper 25598749 Paper 25577037 Paper 25557051 Paper 25538794 Paper 25534989 Paper 25528416 Paper 25484371 Paper 25453052 Paper 25414798 Paper 25310102 Paper 25290883 Paper 25092823 Paper 25054455 Paper 25046446 Paper 25002298 Paper 24919064 Paper 24733297 Paper 24628232 Paper 24615140 Paper 24586033 Paper 24528897 Paper 24519735 Paper 24508590 Paper 24498130 Paper 24418777 Paper 24349641 Paper 24316121 Paper 24211446 Paper 24131154 Paper 24089360 Paper 24084585 Paper 24018188 Paper 23941554 Paper 23927793 Paper 23890825 Paper 23885640 Paper 23884467 Paper 23761473 Paper 23636795 Paper 23608491 Paper 23570607 Paper 23523817 Paper 23495255 Paper 23473679 Paper 23423342 Paper 23418722 Paper 23382385 Paper 23372818 Paper 23307920 Paper 23255623 Paper 23251481 Paper 23243322 Paper 23220422 Paper 23216815 Paper 23205699 Paper 22952997 Paper 22945374 Paper 22887753 Paper 22819840 Paper 22819765 Paper 22791936 Paper 22780870 Patent 9493537 Patent 9463255 Patent 9180214 Patent 8986651

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This project aims to develop drug carriers that can both act as ultrasound contrast agents and therapeutic delivery vehicles activated by specific ultrasound pulses. These carriers must contain both a gas component for ultrasound contrast as well as a therapeutic molecule that retains its bioactivity once delivered to a target site. The carrier formulations under investigation are made primarily of lipids and inert gases for biocompatibility. Challenges include incorporating an effective amount of therapeutic molecules without compromising contrast abilities. These challenges are being overcome through chemical conjugation of a therapeutic molecule to the lipids composing the microbubble shell. Intermediate goals include lipid-based particles that can release drug upon insonation but lack substantial contrast enhancing capabilities, such as liposomal formulations. Ensuring that the formulation is still capable of ultrasound contrast enhancement as well as ultrasound destruction is an additional intermediate goal. To further multi-level targeting, various targeting ligands can also be conjugated to the microbubble shell. Initially, toxicity assays in cell culture are used in conjunction with fluorescence microscopy to determine intracellular uptake of both the drug and the lipid vehicle. Flow cytometry will also be employed to validate induction of apoptosis as opposed to cytostatic affects or necrosis.

View original record on NIH RePORTER →